Small molecule inhibitors undergoing clinical trials includes Curcumin (phase III, targeting NF-kB in brain tumor) [180], Metformin [181] (phase III, targeting ZEB1, Slug, Twist in breast cancer), Omo-103 [182,183] (phase I), and Disulfiram [184] (phase II, targeting ERK/NF-kB/Snail pathway in germ cell tumors). This evidence concerns the gene NFKB1 and germ cell tumor.